0
0
Published: April 19, 2026
NEW YORK — For millions of adults navigating the emotional and physical toll of thinning hair, low-dose oral minoxidil has emerged as a convenient, “off-label” alternative to messy foams and topical liquids. However, a new study from the New York University (NYU) Grossman School of Medicine suggests that the sprint toward hair regrowth may have a finish line. Researchers found that while the medication significantly boosts hair density and thickness early on, these improvements tend to plateau within the first three to six months of treatment.
The retrospective study, published April 14, 2026, in the Journal of the American Academy of Dermatology, provides a crucial reality check for patients and clinicians alike. While the drug remains an effective tool for managing androgenetic alopecia (pattern hair loss), the findings suggest that “more time” does not necessarily equal “more hair” after the initial half-year mark.
The Plateau Effect: What the Data Shows
To understand the long-term trajectory of oral minoxidil, NYU researchers reviewed the records of 178 patients treated for androgenetic alopecia between January 2020 and October 2025. Each patient had at least one baseline measurement and a follow-up assessment of their frontal scalp.
The team measured two primary metrics: hair density (the number of hairs per square centimeter) and hair diameter (the thickness of individual strands).
The results revealed a distinct “front-loaded” benefit:
-
Rapid Early Gains: Mean hair density increased by 16.1 hairs per square centimeter within the first 3 to 6 months.
-
The Leveling Off: Between 6 and 12 months, density remained largely stable. By the 12-to-36-month mark, the density reached 19.0 hairs per square centimeter—a statistically significant improvement from baseline, but one that showed no ongoing acceleration.
-
Thickness Trends: Hair diameter followed a similar path, improving early but failing to show additional gains during long-term follow-up.
“The pattern suggests that low-dose oral minoxidil delivers its primary punch relatively early,” the study authors noted. They also observed a slight dip in hair diameter during the longest follow-up window, which they suggested might reflect the natural, underlying progression of pattern hair loss rather than a failure of the medication itself.
Why the Shift to Oral Treatment?
Androgenetic alopecia is the most common cause of hair loss worldwide, affecting roughly 50% of men and a significant portion of women over age 50. For decades, the gold standard has been topical minoxidil (Rogaine). However, compliance is a notorious hurdle.
“Many patients find topical treatments irritating to the scalp, or they simply don’t like the texture it leaves in their hair,” says Dr. Shani Francis, a board-certified dermatologist and hair loss expert. “Oral minoxidil is attracting attention because a once-daily pill is far easier to integrate into a routine.”
Despite its popularity, the pill remains off-label for hair loss. While the FDA approved minoxidil decades ago as a high-dose treatment for hypertension, it is not specifically approved for hair regrowth. Dermatologists circumvent this by prescribing “low-dose” versions—typically 0.625 mg to 5 mg—which are far lower than the doses used for blood pressure.
Managing Expectations: A Tool for Counseling
The significance of the NYU study lies in patient psychology. When people start a hair loss regimen, they often expect a linear progression—imagining their hair will get thicker and thicker the longer they take the pill.
The data suggests a different narrative: if you respond to the drug, your “peak” hair may arrive by month six. After that, the goal shifts from regrowth to maintenance.
For public health, this distinction is vital. Patients who don’t see new sprouts at month nine might assume the drug has stopped working and quit. In reality, staying on the medication is likely what is preventing further loss. Understanding this “plateau” helps patients set realistic goals and stay committed to their treatment plans.
Safety and Side Effects: The Systemic Factor
Because oral minoxidil is systemic—meaning it travels through the entire bloodstream rather than staying on the scalp—it carries a different side-effect profile than topicals.
A 2021 multicenter study of 1,404 patients found the following:
-
Hypertrichosis: 15.1% of patients reported unwanted hair growth on other parts of the body (such as the face or arms).
-
Systemic Effects: Lower percentages of patients experienced lightheadedness, fluid retention (edema), headaches, or an increased heart rate (tachycardia).
-
Tolerance: Only 1.2% of patients had to stop treatment due to systemic side effects.
“Patient selection is essential,” explains Dr. Francis. “Because it can affect blood pressure and heart rate, we have to look at a patient’s cardiovascular history before starting them on a systemic treatment.”
The Broader Evidence Base
The NYU findings align with previous research but add necessary long-term context. A 2022 systematic review confirmed that the drug works in a dose-dependent manner—higher doses generally lead to better density but higher risks of side effects. Furthermore, a 2024 randomized trial found that 1 mg of oral minoxidil performed comparably to 5% topical solution over six months, reinforcing that the oral route is a viable, though not necessarily “superior,” alternative.
Comparison Table: Oral vs. Topical Minoxidil
| Feature | Low-Dose Oral Minoxidil | Topical Minoxidil (5%) |
| Application | Once-daily pill | Twice-daily scalp liquid/foam |
| FDA Approval | Off-label for hair loss | FDA-approved |
| Primary Side Effect | Unwanted body hair (Hypertrichosis) | Scalp irritation/dryness |
| Systemic Risk | Low (Blood pressure/Heart rate) | Negligible |
| Compliance | Generally high | Often low |
Limitations of the Study
While the NYU study offers valuable insights, it is not without caveats. As a retrospective study, it looked back at existing records rather than being a controlled clinical trial.
-
No Control Group: Without a “placebo” group, it is impossible to say with 100% certainty that the minoxidil alone caused the density changes.
-
Site Specificity: Researchers only measured the frontal scalp. Hair loss at the crown or temples may respond differently.
-
Adherence: Researchers could not verify if every patient took their pill every single day.
The Bottom Line for Readers
If you are considering oral minoxidil, the “takeaway” is one of tempered optimism. The treatment is effective for many, but it is not a “magic pill” that results in an endless mane.
-
Consult a Specialist: Always work with a dermatologist to ensure you are a safe candidate for systemic medication.
-
Be Patient: Changes take at least three months to become visible.
-
Expect a Plateau: Do not be discouraged if your hair growth “levels off” after six months. This is a normal part of the treatment trajectory.
-
Maintenance is Key: Androgenetic alopecia is a progressive condition. Stopping treatment—even after reaching a plateau—will likely result in the loss of the hair gained.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.medscape.com/viewarticle/low-dose-oral-minoxidil-hair-growth-may-peak-after-6-months-2026a1000c0t
